What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical ...

Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

WHAT: Researchers from the Johns Hopkins Kimmel Cancer Center will present new research findings and receive honors and ...

The Lung Cancer Research Foundation, in partnership with patients, survivors, caregivers, loved ones, industry partners and ...

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness. Patients who are newly diagnosed ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotechnology firm Nuvalent said Monday that its drug for a genetically defined type of lung cancer shrank tumors in ...

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug ...